Arthritis & Rheumatology Associates of South Jersey PC

Arthritis & Rheumatology Associates of South Jersey PC was paid $53.34M by Medicaid between Jan 2018 and Nov 2024, across 77 billing codes. Its largest line is J1745, Injection, infliximab, excludes biosimilar, 10 mg — 47% of everything it billed.

33Billing provider infoARTHRITIS & RHEUMATOLOGY ASSOCIATES OF SOUTH JERSEY PC
VINELAND, NJ 08360

33aNPI1255344594assigned 08/15/2006

33bProvider typeRheumatology Physician

28Total paid$53.34M

24GClaims192,190

24DCodes billed77

24AFirst – last monthJan 2018 – Nov 2024

Compared with peers

Next to other Rheumatology Physician providers in New Jersey

Rank by total paid#1 of 34

Median peer was paid$33K

This provider vs. median1,629×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	25,514	$11.14M
2019	17,114	$5.54M
2020	19,789	$5.29M
2021	30,865	$8.91M
2022	42,723	$8.86M
2023	33,523	$7.37M
2024incomplete	22,662	$6.24M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J1745	Injection, infliximab, excludes biosimilar, 10 mg	47%	22,521	11,465	$25.08M
J1602	Injection, golimumab, 1 mg, for intravenous use	13%	5,053	2,937	$7.06M
J0490	Injection, belimumab, 10 mg	10%	4,949	1,855	$5.41M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	7.7%	20,948	18,222	$4.09M
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	7.3%	2,680	1,558	$3.89M
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	2.5%	526	461	$1.33M
96415		2.5%	15,105	13,116	$1.31M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	1.3%	15,015	14,195	$672K
20610		1.0%	8,901	7,473	$547K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	<1%	373	265	$527K
77080		<1%	5,259	4,895	$467K
J7323	Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose	<1%	604	336	$347K

65 more codes

99214	Doctor's office visit, returning patient (more involved)	<1%	4,766	$292K
96375	Therapeutic injection; each additional sequential IV push	<1%	7,641	$210K
J0897	Injection, denosumab, 1 mg	<1%	431	$174K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	7,803	$167K
96401		<1%	2,317	$142K
90750		<1%	795	$119K
73100		<1%	3,591	$102K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	2,612	$91K
73120		<1%	3,613	$91K
73560		<1%	2,948	$82K
J3489	Injection, zoledronic acid, 1 mg	<1%	1,510	$79K
72110		<1%	1,974	$77K
99244	Office or other outpatient consultation, moderate to high complexity	<1%	429	$75K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	4,461	$68K
20550		<1%	1,903	$64K
20605		<1%	1,655	$61K
73030		<1%	1,556	$51K
20611		<1%	607	$50K
J2357	Injection, omalizumab, 5 mg	<1%	41	$45K
20600		<1%	995	$43K
71046	Radiologic examination, chest; 2 views	<1%	1,371	$41K
73600		<1%	1,353	$40K
73620		<1%	1,347	$39K
99204	Doctor's office visit, new patient (more involved)	<1%	415	$37K
90688		<1%	2,923	$34K
90732		<1%	409	$32K
90670		<1%	243	$32K
96367		<1%	1,056	$29K
73521		<1%	826	$26K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	4,741	$24K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	4,483	$23K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	24	$19K
64493		<1%	63	$14K
90472	Immunization administration, each additional vaccine (list separately)	<1%	581	$13K
73070		<1%	289	$12K
99215	Doctor's office visit, returning patient (complex)	<1%	170	$12K
72202		<1%	402	$12K
J7321	Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose	<1%	304	$11K
72040		<1%	404	$11K
90715		<1%	228	$10K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	216	$10K
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	943	$9K
73565		<1%	318	$8K
99243		<1%	37	$5K
64494		<1%	50	$4K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	4,602	$4K
99203	Doctor's office visit, new patient (routine)	<1%	58	$4K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	4,323	$4K
90671		<1%	14	$3K
S0028	Injection, famotidine, 20 mg	<1%	3,042	$3K
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	569	$3K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	594	$2K
77002		<1%	41	$780.52
72200		<1%	13	$466.67
72070		<1%	14	$390.39
90661		<1%	26	$292.98
95117		<1%	121	$196.85
G0008	Administration of influenza virus vaccine	<1%	622	$188.96
99406		<1%	17	$186.68
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	106	$50.63
G8417	Bmi is documented above normal parameters and a follow-up plan is documented	0%	1,038	$0.00
90653		0%	13	$0.00
90662		0%	51	$0.00
G8420	Bmi is documented within normal parameters and no follow-up plan is required	0%	122	$0.00
G0009	Administration of pneumococcal vaccine	0%	26	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSOLOWAY, STEPHEN (AUTHORIZED OFFICIAL)